Gunzler, Steven A. MD*†; Pavel, Misha PhD‡; Koudelka, Caroline MPH§; Carlson, Nichole E. PhD∥; Nutt, John G. MD*
*Parkinson's Disease Research, Education, and Clinical Center, Portland VA Medical Center, Portland, OR; and †Parkinson Center of Oregon, ‡Department of Biomedical Engineering, §Oregon Clinical and Translational Research Institute, and ∥Division of Biostatistics, Department of Public Health and Preventive Medicine, Oregon Health and Sciences University, Portland, OR.
Address correspondence and reprint request to Steven Gunzler, MD, Movement Disorders Center, The Neurological Institute, University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, 11100 Euclid Ave, Cleveland, OH 44106; E-mail: [email protected]
This work was supported by the Parkinson Disease Research, Education, and Clinical Center at the Portland VA Medical Center; the Oregon Clinical and Translational Research Institute at Oregon Health and Sciences University (supported in part by PHS grant, UL1 RR024140-01); and a National Institutes of Health grant, R01 NS021062-20. Britannia Pharmaceuticals provided apomorphine.
doi: 10.1097/WNF.0b013e3181684c22
